Named on 2 rounds in the feed.
Rounds from 2025-11-17 to 2026-01-28
ROUNDS
2
joined, none as lead
ROUNDS JOINED · USD
$377M
across 2 rounds
CO-INVESTORS
21
named beside it
Named on 2 rounds in the feed.
Rounds from 2025-11-17 to 2026-01-28
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Cellares Cellares specializes in advanced manufacturing technologies for cell therapy, targeting biopharmaceutical companies and healthcare providers. | Series D Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $257M | 2026-01-28 | [ PART ] |
Solve Therapeutics Novel antibody-drug conjugates (ADCs) for cancer treatment targeted at solid tumors and optimized for payload delivery using proprietary technology. | Funding round Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-11-17 | [ PART ] |